Bio-Techne (TECH) Other Non-Current Assets (2010 - 2026)
Bio-Techne's quarterly Other Non-Current Assets came in at $264.4 million in Q1 2026, down 1.72% year-on-year from $269.0 million in Q1 2025, and down 1.02% quarter-over-quarter from $267.1 million in Q4 2025.
Bio-Techne has reported Other Non-Current Assets for 17 years, with the latest figure at $264.4 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 1.72% year-over-year to $264.4 million; the trailing twelve-month figure through Mar 2026 stood at $264.4 million (down 1.72% YoY), and the FY2025 full-year result was $12.3 million, down 95.33% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $264.4 million, down from $267.1 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $285.3 million in Q2 2023, with the low at $1.0 million in Q4 2024.
- Average Other Non-Current Assets over 5 years is $159.6 million, with a median of $264.3 million recorded in 2024.
- Year-over-year, Other Non-Current Assets sank 96.64% in 2024 and soared 25409.46% in 2025.
- Tracing TECH's Other Non-Current Assets over 5 years: stood at $53.2 million in 2022, then slumped by 49.91% to $26.6 million in 2023, then tumbled by 96.07% to $1.0 million in 2024, then soared by 25409.46% to $267.1 million in 2025, then dropped by 1.02% to $264.4 million in 2026.
- The last three Other Non-Current Assets figures came in at $264.4 million (Q1 2026), $267.1 million (Q4 2025), and $276.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Bio-Techne | 7.92 Bn | 7.71 Bn | 208.29 Mn | 264.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 264.37 Mn |
| Dec 31, 2025 | 267.08 Mn |
| Sep 30, 2025 | 276.56 Mn |
| Jun 30, 2025 | 12.33 Mn |
| Mar 31, 2025 | 268.99 Mn |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | 9.46 Mn |
| Jun 30, 2024 | 264.27 Mn |
| Mar 31, 2024 | 272.14 Mn |
| Dec 31, 2023 | 26.65 Mn |
| Sep 30, 2023 | 281.58 Mn |
| Jun 30, 2023 | 285.30 Mn |
| Mar 31, 2023 | 283.35 Mn |
| Dec 31, 2022 | 53.19 Mn |
| Sep 30, 2022 | 53.90 Mn |
| Jun 30, 2022 | 46.83 Mn |
| Mar 31, 2022 | 45.98 Mn |
| Dec 31, 2021 | 37.11 Mn |
| Sep 30, 2021 | 11.59 Mn |
| Jun 30, 2021 | 11.58 Mn |
| Mar 31, 2021 | 11.59 Mn |
| Dec 31, 2020 | 11.34 Mn |
| Sep 30, 2020 | 10.28 Mn |
| Jun 30, 2020 | 13.52 Mn |
| Mar 31, 2020 | 12.17 Mn |
| Dec 31, 2019 | 9.25 Mn |
| Sep 30, 2019 | 5.59 Mn |
| Jun 30, 2019 | 5.18 Mn |
| Mar 31, 2019 | 5.12 Mn |
| Dec 31, 2018 | 5.01 Mn |
| Sep 30, 2018 | 5.10 Mn |
| Jun 30, 2018 | 5.27 Mn |
| Mar 31, 2018 | 27.06 Mn |
| Dec 31, 2017 | 43.41 Mn |
| Sep 30, 2017 | 44.57 Mn |
| Jun 30, 2017 | 3.62 Mn |
| Mar 31, 2017 | 2.43 Mn |
| Dec 31, 2016 | 42.69 Mn |
| Sep 30, 2016 | 4.11 Mn |
| Jun 30, 2016 | 1.92 Mn |
| Mar 31, 2016 | 1.47 Mn |
| Dec 31, 2015 | 1.59 Mn |
| Sep 30, 2015 | 1.76 Mn |
| Jun 30, 2015 | 1.85 Mn |
| Mar 31, 2015 | 1.94 Mn |
| Dec 31, 2014 | 1.70 Mn |
| Sep 30, 2014 | 1.83 Mn |
| Jun 30, 2014 | 1.08 Mn |
| Mar 31, 2014 | 2.27 Mn |
| Dec 31, 2013 | 2.37 Mn |
| Sep 30, 2013 | 2.49 Mn |
| Jun 30, 2013 | 3.33 Mn |
| Mar 31, 2013 | 3.08 Mn |
| Dec 31, 2012 | 3.03 Mn |
| Sep 30, 2012 | 2.84 Mn |
| Jun 30, 2012 | 1.85 Mn |
| Mar 31, 2012 | 1.62 Mn |
| Dec 31, 2011 | 1.22 Mn |
| Sep 30, 2011 | 11.30 Mn |
| Jun 30, 2011 | 1.32 Mn |
| Mar 31, 2011 | 1.20 Mn |
| Dec 31, 2010 | 440,000.00 |
| Sep 30, 2010 | 477,000.00 |
| Jun 30, 2010 | 523,000.00 |